James Howard Tonsgard to Neurofibromatosis 2
This is a "connection" page, showing publications James Howard Tonsgard has written about Neurofibromatosis 2.
Connection Strength
0.778
-
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025 Jul; 173(3):751-757.
Score: 0.233
-
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506.
Score: 0.206
-
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
Score: 0.158
-
The ophthalmologic presentation of NF-2 in childhood. J Pediatr Ophthalmol Strabismus. 1993 Sep-Oct; 30(5):327-30.
Score: 0.103
-
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009 Aug 15; 15(16):5032-5039.
Score: 0.078